Implementation of the ICH E9 (R1) addendum in vaccine efficacy studies: the hypothetical and principal stratum strategies.

Over the past decades, the primary interest in vaccine efficacy evaluation has mostly been on the effect observed in trial participants complying with the protocol requirements (per protocol analysis). The ICH E9 (R1) addendum provides a structured framework to formulate the clinical questions of interest and formalize them as estimands. In this paper, the estimand framework is retrospectively implemented in a human papillomavirus (HPV) phase 3 trial, where the vaccine efficacy was originally estimated on the per protocol set. We focus on two strategies for dealing with the presence of intercurrent events: the hypothetical and the principal stratum strategies. We address the interpretation of these two estimands, their estimation as well as articulation of the underlying identifiability assumptions. Finally, we leverage the results of the HPV application to formulate general considerations regarding the implementation of the ICH E9 (R1) addendum in vaccine efficacy studies.